SPOP and prostate cancer: PXN expression was relatively high in ERG1- and FLI1-fusion-positive prostate cancers and SPOP-mutant prostate cancer, but it was relatively low in ETV1- and ETV4-fusion-positive prostate cancers (Figure S1b).